Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash & Equivalents: 2013-2024

Historic Cash & Equivalents for Zevra Therapeutics (ZVRA) over the last 10 years, with Dec 2024 value amounting to $33.8 million.

  • Zevra Therapeutics' Cash & Equivalents rose 0.74% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.4 million, marking a year-over-year increase of 0.74%. This contributed to the annual value of $33.8 million for FY2024, which is 21.52% down from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Cash & Equivalents is $33.8 million, which was down 21.52% from $43.0 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Cash & Equivalents registered a high of $112.3 million during FY2021, and its lowest value of $4.2 million during FY2020.
  • In the last 3 years, Zevra Therapeutics' Cash & Equivalents had a median value of $43.0 million in 2023 and averaged $47.4 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 2,566.65% in 2021, then slumped by 41.73% in 2022.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Cash & Equivalents stood at $4.2 million in 2020, then spiked by 2,566.65% to $112.3 million in 2021, then crashed by 41.73% to $65.5 million in 2022, then crashed by 34.24% to $43.0 million in 2023, then dropped by 21.52% to $33.8 million in 2024.